PR Newswire · Press release
INOVIO to Report Third Quarter 2026 Financial Results on November 10, 2026
Original release from PR Newswire
As distributed by PR Newswire, unedited.
PLYMOUTH MEETING, Pa., Nov. 2, 2026 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that its third quarter 2026 financial results will be released after the market close on November 10, 2026. Following the release, INOVIO will host a live conference call and webcast at 4:30 p.m. ET to discuss the financial results and provide a general business update.
A live webcast of the call will be available on the company's website at https://ir.inovio.com/events-and-presentations. The webcast will be archived and available for replay for 90 days following the event.
About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing innovative DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of DNA medicines that enable the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com
Contacts
Media: Josephine Galatioto - ICR Healthcare, inoviopr@icrhealthcare.com
Investors: Peter Vozzo - ICR Healthcare, (443) 213-0505, peter.vozzo@icrhealthcare.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-to-report-third-quarter-2026-financial-results-on-november-10-2026-302926888.html
SOURCE INOVIO Pharmaceuticals, Inc.
